Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of Multiple-Dose CM338 in Healthy Subjects
NCT05371379Phase 1Completed
- Sponsor
- Keymed Biosciences
- Start
- May 2022
- Primary completion
- Nov 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CM338 in IgA nephropathy (IgAN) (5 arms), sponsored by Keymed Biosciences. Primary endpoint: Incidence of Adverse Events. Started May 2022; status: completed.
02
Drugs
CM338
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT05371379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05371379.